Skip to main content

SARS-CoV-2 spike glycoprotein (mutated F817P + A892P + A899P + A942P + K986P + V987P) is a SARS-CoV-2 Fragment protein, in the 1 to 1205 aa range, expressed in HEK 293, with >95% purity and suitable for SDS-PAGE.

Be the first to review this product! Submit a review

Images

SDS-PAGE -  SARS-CoV-2 spike glycoprotein (mutated F817P + A892P + A899P + A942P + K986P + V987P) (AB288545), expandable thumbnail

Key facts

Purity

>95% SDS-PAGE

Expression system

HEK 293 cells

Tags

His tag C-Terminus

Applications

SDS-PAGE

Biologically active

No

Reactivity data

Application

SDS-PAGE

Reactivity

Reacts

Dilution info

-

Notes

-

Target data

Function

Spike protein S1Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed:32142651, PubMed:33607086, PubMed:32155444). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed:34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed:32221306, PubMed:32075877). Alternatively, may use NRP1/NRP2 (PubMed:33082294, PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed:32817270).Spike protein S2Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.Spike protein S2'Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.

Alternative names

Recommended products

SARS-CoV-2 spike glycoprotein (mutated F817P + A892P + A899P + A942P + K986P + V987P) is a SARS-CoV-2 Fragment protein, in the 1 to 1205 aa range, expressed in HEK 293, with >95% purity and suitable for SDS-PAGE.

Alternative names

Key facts

Purity

>95% SDS-PAGE

Expression system

HEK 293 cells

Applications

SDS-PAGE

Accession
P0DTC2-1
Animal free

No

Species

SARS-CoV-2

Concentration
Loading...
Storage buffer

pH: 7.4
Constituents: 99% PBS

Sequence info

Amino acid sequence

Accession

Protein length

Fragment

Predicted molecular weight

140 kDa

Amino acids

1 to 1205

Nature

Recombinant

Tags

His tag C-Terminus

Specifications

Form

Liquid

General info

Function

Spike protein S1

Sequence similarities

Belongs to the betacoronaviruses spike protein family.

Post-translational modifications

The cytoplasmic Cys-rich domain is palmitoylated. Palmitoylated spike proteins drive the formation of localized ordered cholesterol and sphingo-lipid-rich lipid nanodomains in the early Golgi, where viral budding occurs.

Storage

Shipped at conditions

Dry Ice

Appropriate long-term storage conditions

-80°C

Storage information

Avoid freeze / thaw cycle

Notes

SARS-CoV-2 South African (Beta) Variant (B.1.351/501Y.V2) spike glycoprotein. This varient contains amino acid changes L18F, D80A, D215G, del242-244, K417N, E484K, N501Y, D614G, A701V relative to Wuhan-Hu-1.

The protein contains six proline amino acid changes (commonly known as Hexapro) to stabilize it in a trimeric pre-fusion state. The furin cleavage site has been altered to 'SRAS' and deactivated.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The SARS-CoV-2 Spike Glycoprotein also known as COVID-19 Spike Protein is a trimeric protein weighing approximately 180-200 kDa. It is located on the surface of the SARS-CoV-2 virus playing an important role in virus infectivity. The protein comprises two main subunits S1 and S2 which facilitate attachment to and fusion with host cells. The S1 subunit contains the receptor binding domain (RBD) which specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptor. The Spike Glycoprotein is expressed in infected host cells mainly in the respiratory tract allowing the virus to enter and initiate replication.

Biological function summary

The SARS-CoV-2 Spike Glycoprotein initiates viral entry by interacting with the host cell's ACE2 receptor which leads to viral fusion and entry into the cell's cytoplasm. The protein is part of the virion structure and forms the visible spike on the virion's surface. Upon binding a conformational change triggers the fusion of viral and cellular membranes a vital step for the viral lifecycle. The multimeric nature of the Spike Protein facilitates its interaction with antibodies including those known as 'anti-spike antibodies' which can neutralize the virus and prevent cell infection.

Pathways

The Spike Glycoprotein plays a significant role in the viral infection process and immune response pathways. It is central to the receptor-mediated endocytosis pathway where the virus is internalized into host cells. The protein’s interaction with ACE2 modifies downstream signaling pathways potentially altering host cell functions. Related proteins in these pathways include the ACE2 receptor and the cellular protease TMPRSS2 which primes the Spike Protein for fusion and viral entry.

Associated diseases and disorders

The Spike Glycoprotein is chiefly implicated in COVID-19 the disease caused by SARS-CoV-2. The interaction with ACE2 is not just vital for infection but also contributes to the disease's symptomatology as ACE2 is involved in regulating blood pressure and inflammation. Additionally the Spike Protein's role in viral entry makes it a target for therapeutic interventions including 'anti-spike antibodies' and vaccines aimed at blocking this process to prevent infection. The protein's relevance to COVID-19 has led to significant interest in developing diagnostic and therapeutic tools such as 'antibodies COVID' that target the Spike Glycoprotein to manage the disease effectively.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

1 product image

  • SDS-PAGE -  SARS-CoV-2 spike glycoprotein (mutated F817P + A892P + A899P + A942P + K986P + V987P) (ab288545), expandable thumbnail

    SDS-PAGE - SARS-CoV-2 spike glycoprotein (mutated F817P + A892P + A899P + A942P + K986P + V987P) (ab288545)

    Reducing SDS-PAGE analysis of ab288545 (2.5 μg).

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com